Sequent Scientific and Viyash Life Sciences Announce Huge Rs 8,000 Crore Merger to Create Animal Pharma Leader

Sequent Scientific and Viyash Life Sciences are joining forces in a massive Rs 8,000 crore merger. This move will create a powerful new company with expertise in animal pharmaceuticals and strong capabilities across the global pharmaceutical market, as confirmed in a stock exchange filing.

The merger will combine Sequent Scientific’s listed company and Viyash Life Sciences, which is not publicly listed. In the last financial year, Sequent made operating profits of around Rs 100 crore, while Viyash earned about Rs 150 crore. Carlyle, a major investor in both companies, backs this merger.

Sequent Scientific’s CEO, Rajaram Narayanan, shared his excitement about this big step, saying it will help the company grow in research and development, particularly in animal health. Viyash’s CEO, Haribabu Bodepudi, also expressed his enthusiasm, calling the merger a perfect match of two companies committed to innovation and operational excellence.

As part of the deal, Viyash shareholders will receive 56 shares of Sequent for every 100 Viyash shares they own. This will expand Sequent Scientific’s shares to over 42 crore, and the promoters will hold around 62.4% of the combined company. The merger values the new entity at around Rs 8,192 crore based on Thursday’s closing prices.

Both companies plan to use their strengths in manufacturing and global customer connections to expand their market reach and improve efficiency. Together, they will operate 16 manufacturing plants, including 10 that are approved by the US FDA. Financial advisors, law firms, and accounting firms played key roles in making this merger happen.

This merger is expected to create new opportunities for both companies, with a strong focus on animal health and global expansion.